Development of neuropeptide drugs that cross the blood-brain barrier. - Wikidata - awgldk - TriplyDB

Development of neuropeptide drugs that cross the blood-brain barrier.

Development of neuropeptide drugs that cross the blood-brain barrier.

http://www.wikidata.org/entity/Q33569277

about

Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain M1 and M2 immune activation in Parkinson's Disease: Foe and ally?A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier A drug delivery strategy: binding enkephalin to asialoglycoprotein receptor by enzymatic galactosylation The use of immunoliposome for nutrient target regulation (a review).Structure-specific effects of lipidated oxytocin analogs on intracellular calcium levels, parental behavior, and oxytocin concentrations in the plasma and cerebrospinal fluid in mice.Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides.Advances in strategies to improve drug delivery to brain tumors.Selected Gamma Aminobutyric Acid (GABA) Esters may Provide Analgesia for Some Central Pain Conditions Cell-type specific regulation of cortical excitability through the allatostatin receptor system.Immunity and behavior: antibodies alter emotion Lipo-oxytocin-1, a Novel Oxytocin Analog Conjugated with Two Palmitoyl Groups, Has Long-Lasting Effects on Anxiety-Related Behavior and Social Avoidance in CD157 Knockout Mice Quorum Sensing Peptides Selectively Penetrate the Blood-Brain Barrier.sCD44 internalization in human trabecular meshwork cells.Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins Neurological disorders and therapeutics targeted to surmount the blood-brain barrier Reactivity of Metal-Free and Metal-Associated Amyloid-β with Glycosylated Polyphenols and Their Esterified Derivatives.Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists Targeted drug delivery to treat pain and cerebral hypoxia Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands Polymeric nanoparticles for the drug delivery to the central nervous system.Dynorphin peptides differentially regulate the human kappa opioid receptor Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Early Loss of Blood-Brain Barrier Integrity Precedes NOX2 Elevation in the Prefrontal Cortex of an Animal Model of Psychosis.Development of a bioavailable μ opioid receptor (MOPr) agonist, δ opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance.Peptide pills for brain diseases? Reality and future perspectives.Sweetening pharmaceutical radiochemistry by (18)f-fluoroglycosylation: a short review.Stem cell delivery of therapies for brain disorders.Therapeutic Potential of Natural Product-Based Oral Nanomedicines for Stroke Prevention Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues Neuropeptide systems and new treatments for nicotine addiction.Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles.Increasing the Biological Stability Profile of a New Chemical Entity, UPEI-104, and Potential Use as a Neuroprotectant Against Reperfusion-Injury.Novel cyclic biphalin analogue with improved antinociceptive properties.Current challenges in peptide-based drug discovery.Low Molecular Weight Opioid Peptide Esters Could be Developed as a New Class of Analgesics Structural and biological implications of the binding of Leu-enkephalin and its metal derivatives to opioid receptors.

P2860

Q24647835-BF40679D-6F04-4AF8-A6AF-1D346F1850AF Q24650190-6E83C9D1-D3B4-4C79-A45D-A7F2666C1EC5 Q26991917-0215098F-BC21-4249-ACD8-F90CD14BED87 Q27024667-E19D7988-D2A2-4411-B75F-CC658D616F70 Q28472987-1A9BDABF-2E36-479A-ABE5-BA889B4B37ED Q28537923-E59E7331-7C7F-4935-A8EE-B7DBA6BFA739 Q33263078-93051095-E3A2-4421-9E98-EC020A8BD5F4 Q33771389-6892F943-FB99-479B-B338-D2576D65B369 Q33814126-51ED26FA-E520-4002-BBFB-B905B1DB89BB Q34000631-B1C1ACF4-DBE4-453D-AE10-B5917AB99AAB Q34052708-5F5FA791-3C2E-4D64-8783-29A13C5CC669 Q34154499-255A641F-9BAF-4CAF-81BF-A9600362FA04 Q34270963-223A2687-048B-4E22-929A-359074DA4D89 Q34459188-5A6B1848-3D6B-41F5-90D9-7B901DD8EB8A Q34500499-EA284415-26AE-4AF6-89FB-FF3C0A7E3467 Q34536198-9ED8FF57-F526-49FC-BF2D-77DD84F3B152 Q35671789-AC6FBED7-FF04-4941-8013-8D8A2DB57E0F Q35835788-94C8AADE-D3A3-458C-A52C-7A66EB5F304A Q36119574-0A76F4D7-A6AC-48BC-8E94-53C236E8B9A3 Q36360873-91D7385F-6EFF-468F-96D2-8176A122DC4A Q36464821-60D92608-8C45-4B12-B82B-F75CA4D8C177 Q36591611-F8DE1F18-2E52-4EFC-BA9B-67FA0A24F0EF Q36745738-F1ABE574-F767-4E40-AE68-972DB32055FA Q37076360-1397ACC3-B0DF-4DA1-A035-CB31FFE3ABE2 Q37227827-E026291B-7FF8-4347-A9F7-77BB4479B482 Q37365405-5B0E3146-69DF-44DF-8D23-E1C9BDDF6CF1 Q37707347-7B6EF052-C413-4535-89EB-CDB28F0956C2 Q37714225-92E2E1A5-00E5-4F55-AB35-EFB07A82D7DB Q38096036-F30CC3D2-C279-40C2-8890-17CCD3C6C28D Q38225878-EE968AD7-3E34-4835-A737-46C21881579E Q38237392-5E500345-84FF-40A6-B228-A0173A766376 Q38823069-B4FC843C-0E4E-4514-B637-8090F802CB62 Q39033568-53DB823E-29A6-4CD5-8D98-EC010F79B633 Q39059946-B87698CD-4891-4D09-AE12-CD0ED27C1E44 Q40335819-D46F3463-A0C8-4FF8-A489-8302D1A41D0D Q41333808-DDC68B56-C473-4DF5-8C25-290CBC74BB21 Q41838525-C3A8C2E5-2CBE-41C4-8AC6-0E1F2FDB8CEF Q42778271-59868FE7-1D11-4A63-9E6E-CEFA41B13A72 Q42860558-200BA149-1C48-4DB7-8C13-73BCF5CCEC93 Q44338565-BBFF4363-21E7-4261-BF78-C73955696D8A

P2860

Development of neuropeptide drugs that cross the blood-brain barrier.

http://www.wikidata.org/entity/Q33569277

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Development of neuropeptide drugs that cross the blood-brain barrier.

@ast

Development of neuropeptide drugs that cross the blood-brain barrier.

@en

Development of neuropeptide drugs that cross the blood-brain barrier.

@nl

type

label

Development of neuropeptide drugs that cross the blood-brain barrier.

@ast

Development of neuropeptide drugs that cross the blood-brain barrier.

@en

Development of neuropeptide drugs that cross the blood-brain barrier.

@nl

prefLabel

Development of neuropeptide drugs that cross the blood-brain barrier.

@ast

Development of neuropeptide drugs that cross the blood-brain barrier.

@en

Development of neuropeptide drugs that cross the blood-brain barrier.

@nl

P1433

Q33569277-D757F98C-D642-4CAF-B0DF-928BCB62B77B

P1476

Q33569277-1C1883BF-CCAE-4AAC-98C6-B41C9911E607

P2093

Q33569277-0BBD6CBF-85DE-4272-9E24-5D0DC0B8015A

Q33569277-B8309DD3-5F65-40BF-9AB0-2864BB3C28A9

P2860

Q33569277-0164B713-7B2B-438D-9D4C-376162360DBD

Q33569277-018B8467-8A16-4CAA-BE53-8626B29ED1D8

Q33569277-0A68DCB7-A336-45CD-B3EF-9C0053D8D340

Q33569277-0E228934-A090-48DC-9D0B-6D24D7215D23

Q33569277-0F3CD131-BC9D-41EB-B6C6-6BC59AA5DE49

Q33569277-10E6E626-1FDE-4FF0-9E20-F91DEC5D89ED

Q33569277-15AF18F4-0E63-4809-8B3E-571BC91EF733

Q33569277-16C27639-E526-48F9-9BA4-A2E2F6B5ADAB

Q33569277-171083FA-C0C8-4837-8515-F03DCB0F84F3

Q33569277-17350265-F79B-4C3F-A39E-7F34AA30FDC8

P304

Q33569277-2D044A69-E9DD-4CF6-B46A-CC38EE8C87FC

P31

Q33569277-71E367B5-D530-430B-A833-6926842BC9A0

P356

Q33569277-0F60EF9D-7F05-4F2F-8D57-F1B14315D3AD

P433

Q33569277-825BF036-9B0C-4BE0-B2EB-F891228DCD18

P478

Q33569277-806D1976-3E3B-4D93-97E6-19FD2F86AC28

P577

Q33569277-5D76430A-E0EF-46F0-A039-23255210F133

P5875

Q33569277-40D9D113-1FF2-40F1-8B7C-1229A0E9A5CE

P698

Q33569277-0E9A34BE-044E-46E7-8975-1B5A5AE644E3

P921

Q33569277-6F68B629-4A75-4B4A-8A5A-64F7F3311DCA

P932

Q33569277-252D9148-9740-4203-9575-20EC951AD846

P356

P1433

P1476

Development of neuropeptide drugs that cross the blood-brain barrier.

@en

P2093

Richard D Egleton

http://www.w3.org/2001/XMLSchema#string

Thomas P Davis

http://www.w3.org/2001/XMLSchema#string

P2860

Junctions between intimately apposed cell membranes in the vertebrate brain

Substance P: structure, function, and therapeutics

Blood-brain barrier transcytosis of insulin in developing rabbits

Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors

Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain

Glycopeptide-membrane interactions: glycosyl enkephalin analogues adopt turn conformations by NMR and CD in amphipathic media.

Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs.

A new multidrug resistance protein at the blood-brain barrier.

Implications of species difference for clinical investigation: studies on the renin-angiotensin system.

Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier.

P304

44-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1602/NEURORX.2.1.44

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8016255

http://www.w3.org/2001/XMLSchema#string

P698

15717056

http://www.w3.org/2001/XMLSchema#string

P921

blood–brain barrier

P932

539319

http://www.w3.org/2001/XMLSchema#string